Following this approach, Acrivon has advanced two drug candidates into human clinical trials. Its lead program, ACR-368, is a selective CHK1/CHK2 inhibitor being evaluated in a registrational-intent Phase 2b trial for patients with recurrent, high-grade endometrial cancer who have progressed after platinum chemotherapy and immunotherapy. Early clinical readouts from the trial have been encouraging. Among patients identified as OncoSignature-positive, ACR-368 has delivered substantially higher response rates ...